Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00249912 · ClinicalTrials.gov registry record · Phase 3

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

A Phase 3 study of Hypercholesterolemia, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
415
Enrollment target
20
Study locations

NCT00249912: Completed Phase 3 study of Hypercholesterolemia, sponsored by Takeda.

NCT00249912 is a Phase 3 study of Hypercholesterolemia that has completed, run by Takeda. The registered enrollment target is 415 participants, below the 810-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00249912, a Phase 3 study of Hypercholesterolemia, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
415 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with rosuvastatin on cholesterol levels in treating patients with elevated cholesterol.

Conditions Studied

Hypercholesterolemia

Interventions

  • DRUG Rosuvastatin
  • DRUG Lapaquistat acetate and rosuvastatin

Study Locations (20)

California

  • - Long Beach
  • - Mission Viejo
  • - Orange
  • - Redondo Beach
  • - Rolling Hills Estates
  • - San Diego
  • - Torrance
  • - Tustin

Florida

  • - DeLand
  • - Fort Lauderdale
  • - Hialeah
  • - Jacksonville
  • - Jupiter
  • - Melbourne

Alabama

  • - Birmingham
  • - Haleyville
  • - Mobile

Connecticut

  • - Avon
  • - Bristol

Arizona

  • - Scottsdale

Trial Details

FieldValue
Enrollment Target 415 participants
Start Date 2005-10
Est. Completion 2007-04
Phase Phase 3
Takeda

408 total trials

What the finished NCT00249912 record still lists

NCT00249912 is an interventional study that assigns participants to a tested intervention. The registered 415 participants enrollment target is mid-sized for trials with a published cap, below the 810-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (49% lower).

The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Rosuvastatin is the first listed.

NCT00249912 names 20 study sites across 5 states, led by California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT00249912 about?

NCT00249912 is a clinical study titled "Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia". The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with rosuvastatin on cholesterol levels in treating patients with elevated cholesterol.

What is the current status of trial NCT00249912?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 415 participants. The study started on 2005-10. Estimated completion is 2007-04.

What conditions does trial NCT00249912 study?

This clinical trial studies the following conditions: Hypercholesterolemia.

What interventions are being tested in trial NCT00249912?

The interventions under investigation include: Rosuvastatin (DRUG), Lapaquistat acetate and rosuvastatin (DRUG).

Who is sponsoring clinical trial NCT00249912?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00249912 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00249912's enrollment target sits among peer trials

415 19th of 62 higher than 44 of 62 other Hypercholesterolemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05142605 · 415 participants · NA

    Evaluation of Grief Therapy Approaches for Bereaved Parents

  • NCT03527537 · 416 participants · Phase 4

    Gestational Diabetes and Pharmacotherapy (GAP)

  • NCT05007782 · 416 participants · Phase 1

    Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

  • NCT05520099 · 416 participants

    Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00249912, the US trial registry maintained by the National Library of Medicine. NCT00249912 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.